We are pleased to announce that the collaborative assessment, OTCA28 – ‘Lung cancer screening in risk groups’ – is now available.
The aim of this EUnetHTA Assessment is to provide a reliable synthesis and analysis of the available evidence on lung cancer screening in risk groups (persons with history of smoking or current smokers, persons with occupational or environmental exposure to radon, asbestos or fine particles, patients with COPD or idiopathic pulmonary fibrosis, or persons with a family history of lung cancer).
- Research question 1: What is the benefit/harm of screening for lung cancer using low-dose computed tomography (LDCT) compared to no (or no systematic) screening in individuals at elevated risk of lung cancer? As there is reason to assume comparability of no screening and screening using chest X-ray, screening for lung cancer using chest X-ray will be taken into account as a comparator, too if reasonable.
- Research question 2: What is the benefit/harm of screening for lung cancer using biomarkers in addition to LDCT compared to screening using LDCT alone in individuals at elevated risk of lung cancer?
- Research question 3: What is the benefit/harm of organizational variations of systematic screening for lung cancer using LDCT (e.g. screening with different intervals, with/without invitation) in individuals at elevated risk of lung cancer?
- Research question 4: What is the best strategy to inform individuals in the target group about a lung cancer screening program to optimize an informed choice regarding participation?
Please use the following links to access all documentation:
OTCA28 – Final Assessment Report
OTCA28 – Comments from external experts on 2nd draft assessment
OTCA28 – Comments from external experts on 2nd draft project plan
